論文

査読有り 国際誌
2017年6月27日

Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.

Oncotarget
  • Toshiyuki Satoh
  • ,
  • Takeo Tatsuta
  • ,
  • Shigeki Sugawara
  • ,
  • Akiyoshi Hara
  • ,
  • Masahiro Hosono

8
26
開始ページ
42466
終了ページ
42477
記述言語
英語
掲載種別
DOI
10.18632/oncotarget.17198

Malignant mesothelioma is an aggressive cancer with limited therapeutic options. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a multifunctional protein with anti-cancer activity. The effects of pemetrexed, cisplatin, and cSBL were evaluated in mesothelioma and normal mesothelial cell lines. We evaluated cytotoxicity, apoptosis, caspase-3 cleavage and activation, cell proliferation, cell cycle arrest, and levels of cell cycle proteins in H28 cells treated with pemetrexed, cisplatin, and cSBL alone or in combination. Treatment with cSBL alone was cytotoxic to mesothelioma cells. The anti-cancer effect of cSBL was observed in a broader range of cell lines and exhibited greater cancer cell selectivity than pemetrexed or cisplatin. Combination treatment with pemetrexed + cSBL resulted in greater dose-dependent cytotoxicity than pemetrexed + cisplatin, the standard of care in mesothelioma. The synergistic effect of pemetrexed + cSBL was mediated by the cytostatic effect of pemetrexed and the cytotoxic effect of cSBL. It thus appears that cSBL has therapeutic potential for the treatment of mesothelioma.

リンク情報
DOI
https://doi.org/10.18632/oncotarget.17198
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28476017
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522080